Want to see HK:1612 full AI Analyst Report?
Vincent Medical Holdings Limited (1612) AI Stock Analysis
Vincent Medical Holdings Limited
(HKEX:1612)
The stock earns a moderately strong score driven primarily by a solid financial profile, with profitability and margins rebounding and a conservative balance sheet, while an undemanding valuation with a low P/E and high dividend yield further supports the rating. These positives are tempered by a history of cyclical revenue and earnings and uneven free cash flow, alongside neutral-to-soft technicals that show limited current price momentum, keeping the score below the top tier.
Vincent Medical Holdings Limited (1612) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 464.82M
- Dividend Yield
- 6.48%
- Average Volume (3M)
- 200.19K
- Price to Earnings (P/E)
- 4.8
- Beta (1Y)
- 0.83
- Revenue Growth
- 10.95%
- EPS Growth
- 9.26%
- Country
- Hong Kong
- Employees
- 1,556
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Vincent Medical Holdings Limited Business Overview & Revenue Model
Company Description
Vincent Medical Holdings Limited is an investment holding company engaged in the comprehensive process of designing, manufacturing, marketing, and distributing medical devices. Its operations are bifurcated into two main business models: providing pr...
How the Company Makes Money
Vincent Medical Holdings Limited primarily makes money by selling medical devices and related consumables to healthcare providers and distribution channels. Revenue is generated from (i) sales of respiratory care products (typically used in hospital...
Vincent Medical Holdings Limited Financial Statement Overview
Summary
Score reflects recovered profitability with low double-digit margins, a conservatively financed balance sheet with growing equity and moderate debt, offset by cyclical revenue and earnings and volatile free cash flow that weakens cash conversion.
Income Statement
72PositiveBalance Sheet
80PositiveCash Flow
58Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 964.90M | 932.78M | 800.96M | 717.97M | 629.24M | 777.72M |
| Gross Profit | 333.74M | 327.44M | 259.99M | 240.39M | 147.83M | 243.83M |
| EBITDA | 164.90M | 170.76M | 114.39M | 104.11M | 29.95M | 114.55M |
| Net Income | 96.30M | 104.38M | 69.17M | 57.27M | -17.40M | 60.70M |
Balance Sheet | ||||||
| Total Assets | 1.27B | 1.17B | 919.68M | 786.61M | 726.70M | 846.15M |
| Cash, Cash Equivalents and Short-Term Investments | 199.93M | 250.87M | 173.44M | 175.78M | 159.34M | 173.17M |
| Total Debt | 240.66M | 177.42M | 99.65M | 37.38M | 60.39M | 62.96M |
| Total Liabilities | 546.08M | 498.33M | 336.33M | 243.52M | 228.09M | 245.72M |
| Stockholders Equity | 715.77M | 664.65M | 578.55M | 541.84M | 498.01M | 598.36M |
Cash Flow | ||||||
| Free Cash Flow | -25.52M | 54.64M | -26.52M | 61.28M | 57.67M | 94.48M |
| Operating Cash Flow | 59.99M | 168.42M | 73.48M | 124.97M | 76.27M | 119.43M |
| Investing Cash Flow | -86.77M | -119.77M | -98.81M | -62.37M | -18.61M | -20.69M |
| Financing Cash Flow | 20.84M | 27.34M | 26.39M | -45.37M | -67.84M | -101.16M |
Vincent Medical Holdings Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1612, the sentiment is Positive. The current price of 0.70 is below the 20-day moving average (MA) of 0.71, above the 50-day MA of 0.68, and below the 200-day MA of 0.78, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 54.84 is Neutral, neither overbought nor oversold. The STOCH value of 54.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1612.
Vincent Medical Holdings Limited Peers Comparison
Overall Rating
HK:178972Outperform- HK:161271.1Outperform
HK:217267Neutral
HK:185865Neutral
HK:666961.6Neutral
HK:999646Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1789 | 72Outperform | HKD 5.05B | 11.36 | 13.24% | 2.59% | 16.15% | 31.89% |
| HK:1612 | 71Outperform | HKD 468.67M | 4.77 | 13.95% | 6.48% | 10.95% | 9.26% |
| HK:2172 | 67Neutral | HKD 4.71B | 21.26 | 10.38% | 1.74% | 3.83% | -27.04% |
| HK:1858 | 65Neutral | HKD 5.01B | 17.60 | 9.20% | 5.45% | 10.27% | 79.65% |
| HK:6669 | 62Neutral | HKD 1.64B | -27.66 | -3.50% | ― | 9.36% | -153.54% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:9996 | 46Neutral | HKD 2.55B | -15.11 | -7.65% | ― | 21.23% | 36.89% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1612 | Vincent Medical Holdings Limited | 0.71 | -0.09 | -11.25% | |
| HK:9996 | Peijia Medical Ltd. | 3.77 | -2.00 | -34.66% | |
| HK:6669 | Acotec Scientific Holdings Limited | 5.22 | -6.78 | -56.50% | |
| HK:1789 | AK Medical Holdings Ltd. | 4.56 | -1.10 | -19.42% | |
| HK:1858 | Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H | 7.38 | -11.26 | -60.39% | |
| HK:2172 | MicroPort NeuroTech Limited | 8.05 | -3.29 | -29.02% |
Vincent Medical Holdings Limited Corporate Events
Vincent Medical Sets August Board Meeting to Approve Interim Results and Dividend
Vincent Medical Holdings Limited has scheduled a board meeting for 25 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also consider the publication of these interim results and evaluate the...
Vincent Medical Shareholders Approve All AGM Resolutions and Governance Updates
Vincent Medical Holdings Limited reported that all resolutions at its annual general meeting on 20 May 2026 were approved by shareholders, including adoption of the 2025 audited financial statements and a final dividend of HK2.6 cents per share. Shar...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026